Insmed Incorporated (INSM) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

question simply press star followed by the number one on your telephone keypad it is now my pleasure to turn the call over to Brian Dunn you may begin thank you Amy good day everyone and welcome to today's conference call in which we will discuss insmed's first quarter 2025 financial results and provide an update on our business before we start please note that today's call will include forward-looking statements based on our current expectations These statements represent our judgment as of today and inherently involve risks and uncertainties that may cause actual results to differ materially from the results discussed. Please refer to our filings with the Securities and Exchange Commission for more information concerning the risk factors that could affect the company. The information we will discuss on today's call is meant for the benefit of the investment community. It is not intended for promotional purposes and it is not sufficient for prescribing decisions. I'm joined today by Will Lewis, Chair and Chief Executive Officer, and Sarah Bonstein, Chief Financial Officer, who will each provide prepared remarks, after which they will be joined by Martina Flammer, Chief Medical Officer, for a Q&A session. I will now turn the call over to Will. Thank you, Brian, and welcome everyone. 2025 is off to an exceptionally strong start for InsMed, with our research and development, regulatory, and commercial teams executing on their ambitious goals for the year. Our case delivered another quarter of double-digit year-over-year revenue growth in Q1, and each of our mid to late stage clinical programs are on or ahead of schedule. Perhaps most importantly, we have continued to facilitate the FDA's ongoing review of our NDA filing for brenzocatab and bronchiectasis, which has bee...